Aspirin / butalbital / caffeine Alternatives Compared
Aspirin / butalbital / caffeine | Erenumab | Eptinezumab |
|
---|
Aspirin / butalbital / caffeine | Erenumab | Eptinezumab |
|
|||||||
---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Pain, Migraine, Headache. Aspirin / butalbital / caffeine may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Migraine Prevention, Headache, Migraine. Erenumab may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Migraine Prevention, Chronic Migraine, Headache, Migraine. Eptinezumab may also be used for purposes not listed in this medication guide. |
Related suggestions |
|||||||
More about Aspirin / butalbital / caffeine | More about Erenumab | More about Eptinezumab | ||||||||
Ratings & Reviews | ||||||||||
Aspirin / butalbital / caffeine has an average rating of 8.9 out of 10 from a total of 128 ratings on Drugs.com. 88% of reviewers reported a positive effect, while 6% reported a negative effect. |
Erenumab has an average rating of 5.2 out of 10 from a total of 644 ratings on Drugs.com. 39% of reviewers reported a positive effect, while 43% reported a negative effect. |
Eptinezumab has an average rating of 6.0 out of 10 from a total of 47 ratings on Drugs.com. 51% of reviewers reported a positive effect, while 29% reported a negative effect. |
||||||||
Drug Class | ||||||||||
Side Effects | ||||||||||
Generic Availability | ||||||||||
Lower cost generic |
N/A |
N/A |
||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
Dosage Forms Available | ||||||||||
|
N/A |
N/A |
||||||||
Brand Names | ||||||||||
Farbital, Fiorinal, Fiormor, Fiortal, Fortabs | Aimovig | Vyepti | ||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||
35 hours |
672 hours |
648 hours |
||||||||
CSA Schedule ** View glossary of terms | ||||||||||
Moderate abuse potential
Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
Pregnancy Category | ||||||||||
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
Drug Interactions | ||||||||||
A total of 874 drugs are known to interact with Aspirin / butalbital / caffeine:
|
A total of 2 drugs are known to interact with Erenumab:
|
A total of 2 drugs are known to interact with Eptinezumab:
|
||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
Disease Interactions | ||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|||||||||
First Approval Date | ||||||||||
May 04, 1976 |
N/A |
N/A |
||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||
N/A |
N/A |
N/A |
||||||||
More Information | ||||||||||
Patient resources | ||||||||||
Professional Resources | ||||||||||
Related Treatment Guide | ||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.